No Data
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Leerink Partners维持Pyxis Oncology(PYXS.US)买入评级
Leerink Partners analyst Jeffrey La Rosa maintains $Pyxis Oncology(PYXS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of -6.6%
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
Pyxis Oncology Analyst Ratings
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright analyst Swayampakula Ramakanth maintains $Pyxis Oncology(PYXS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate